Bullfrog AI Holdings, Inc. Warrants
BFRGW
NASDAQ Capital Market0.17
USD
+0.01
- -
CIK
0001829247
ISIN
US12021E1174
Return %
Stock
S&P500
1Y
-62.72
26.84
3Y
-80.73
77.03
5Y
-79.82
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Vininder Singh
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 325 Ellington Blvd. Gaithersburg MD United States of America 20878
- IPO Date
- Jan 20, 2023
- CIK
- 0001829247
- Website
- bullfrogai.com
- Similar Companies
- Business
- Bullfrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) operates as a technology-enabled digital biopharma company that leverages artificial intelligence (AI) and machine learning (ML) to advance drug discovery, development, and clinical trials; its core offerings include the proprietary bfLEAP™ platform, an analytical AI/ML engine employing graph-based analytics and causal AI for multi-dimensional analysis of preclinical and clinical datasets, enabling identification of novel drug targets, patient subgroups, hidden biological relationships, mechanism-of-action elucidation, drug repurposing, and clinical trial optimization; Bullfrog Data Networks™, a scalable AI-driven insights platform powered by bfLEAP™ that delivers visual, disease-centric interfaces for high-dimensional multi-modal data exploration supporting early target identification and strategic R&D decisions; and bfPREP™, a module focused on clinical trial preparation and optimization. The company targets biopharma firms, research institutions, and contract research organizations (CROs), particularly small to mid-sized entities underserved by traditional bioinformatics tools, operating primarily in the United States with global reach through partnerships and serving therapeutic areas involving complex diseases. Founded in 2017 and headquartered in Gaithersburg, Maryland, Bullfrog AI aims to reduce drug development costs (averaging $0.8-$2.8 billion), timelines (8.5 years), and failure rates (nearly 90%) by providing explainable AI solutions that accelerate precision medicine and improve patient outcomes. Recent developments include the June 2025 strategic collaboration with UK-based Sygnature Discovery, under which Sygnature introduces Bullfrog Data Networks™ to its global biopharma clients to enhance drug discovery efficiency and is projected to generate $15-$30 million in revenue for Bullfrog AI through 2028; the July 2025 unveiling of the Bullfrog Data Networks™ solutions library to expand enterprise access to AI-powered biomedical insights; and the September 2025 expansion of its sales and marketing team to drive commercial adoption of clinical trial optimization solutions and bfPREP™; additionally, in October 2024, the company closed a registered direct offering involving pre-funded warrants, supporting ongoing growth initiatives.
Bullfrog AI Holdings, Inc. (NASDAQ:BFRGW) Short Interest Update
Bullfrog AI Holdings, Inc. (NASDAQ:BFRGW) Short Interest Update
Bullfrog AI (NASDAQ:BFRGW) Shares Down 1.6% – Time to Sell?